Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of NeuroAIDS

Huanyu Dou, Cassi B. Grotepas, JoEllyn M McMillan, Christopher J. Destache, Mahesh Chaubal, Jane Werling, James Kipp, Barrett Rabinow, Howard Eliot Gendelman

Research output: Contribution to journalArticle

142 Citations (Scopus)

Abstract

Antiretroviral therapy (ART) shows variable blood-brain barrier penetration. This may affect the development of neurological complications of HIV infection. In attempts to attenuate viral growth for the nervous system, cell-based nanoformulations were developed with the focus on improving drug pharmacokinetics. We reasoned that ART carriage could be facilitated within blood-borne macrophages traveling across the blood-brain barrier. To test this idea, an HIV-1 encephalitis (HIVE) rodent model was used where HIV-1-infected human monocyte-derived macrophages were stereotactically injected into the subcortex of severe combined immunodeficient mice. ART was prepared using indinavir (IDV) nanoparticles (NP, nanoART) loaded into murine bone marrow macrophages (BMM, IDV-NP-BMM) after ex vivo cultivation. IDV-NP-BMM was administered i.v. to mice resulting in continuous IDV release for 14 days. Rhodamine-labeled IDV-NP was readily observed in areas of HIVE and specifically in brain subregions with active astrogliosis, microgliosis, and neuronal loss. IDV-NP-BMM treatment led to robust IDV levels and reduced HIV-1 replication in HIVE brain regions. We conclude that nanoART targeting to diseased brain through macrophage carriage is possible and can be considered in developmental therapeutics for HIV-associated neurological disease.

Original languageEnglish (US)
Pages (from-to)661-669
Number of pages9
JournalJournal of Immunology
Volume183
Issue number1
DOIs
StatePublished - Jul 1 2009

Fingerprint

Indinavir
Macrophages
HIV-1
Brain
Pharmaceutical Preparations
Encephalitis
Blood-Brain Barrier
Rhodamines
SCID Mice
Brain Diseases
Therapeutics
Nanoparticles
Nervous System
HIV Infections
Rodentia
Pharmacokinetics
Bone Marrow
HIV
Growth

ASJC Scopus subject areas

  • Immunology

Cite this

Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of NeuroAIDS. / Dou, Huanyu; Grotepas, Cassi B.; McMillan, JoEllyn M; Destache, Christopher J.; Chaubal, Mahesh; Werling, Jane; Kipp, James; Rabinow, Barrett; Gendelman, Howard Eliot.

In: Journal of Immunology, Vol. 183, No. 1, 01.07.2009, p. 661-669.

Research output: Contribution to journalArticle

Dou, Huanyu ; Grotepas, Cassi B. ; McMillan, JoEllyn M ; Destache, Christopher J. ; Chaubal, Mahesh ; Werling, Jane ; Kipp, James ; Rabinow, Barrett ; Gendelman, Howard Eliot. / Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of NeuroAIDS. In: Journal of Immunology. 2009 ; Vol. 183, No. 1. pp. 661-669.
@article{e69aabb11a8246c6838606bdf69d25b8,
title = "Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of NeuroAIDS",
abstract = "Antiretroviral therapy (ART) shows variable blood-brain barrier penetration. This may affect the development of neurological complications of HIV infection. In attempts to attenuate viral growth for the nervous system, cell-based nanoformulations were developed with the focus on improving drug pharmacokinetics. We reasoned that ART carriage could be facilitated within blood-borne macrophages traveling across the blood-brain barrier. To test this idea, an HIV-1 encephalitis (HIVE) rodent model was used where HIV-1-infected human monocyte-derived macrophages were stereotactically injected into the subcortex of severe combined immunodeficient mice. ART was prepared using indinavir (IDV) nanoparticles (NP, nanoART) loaded into murine bone marrow macrophages (BMM, IDV-NP-BMM) after ex vivo cultivation. IDV-NP-BMM was administered i.v. to mice resulting in continuous IDV release for 14 days. Rhodamine-labeled IDV-NP was readily observed in areas of HIVE and specifically in brain subregions with active astrogliosis, microgliosis, and neuronal loss. IDV-NP-BMM treatment led to robust IDV levels and reduced HIV-1 replication in HIVE brain regions. We conclude that nanoART targeting to diseased brain through macrophage carriage is possible and can be considered in developmental therapeutics for HIV-associated neurological disease.",
author = "Huanyu Dou and Grotepas, {Cassi B.} and McMillan, {JoEllyn M} and Destache, {Christopher J.} and Mahesh Chaubal and Jane Werling and James Kipp and Barrett Rabinow and Gendelman, {Howard Eliot}",
year = "2009",
month = "7",
day = "1",
doi = "10.4049/jimmunol.0900274",
language = "English (US)",
volume = "183",
pages = "661--669",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

TY - JOUR

T1 - Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of NeuroAIDS

AU - Dou, Huanyu

AU - Grotepas, Cassi B.

AU - McMillan, JoEllyn M

AU - Destache, Christopher J.

AU - Chaubal, Mahesh

AU - Werling, Jane

AU - Kipp, James

AU - Rabinow, Barrett

AU - Gendelman, Howard Eliot

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Antiretroviral therapy (ART) shows variable blood-brain barrier penetration. This may affect the development of neurological complications of HIV infection. In attempts to attenuate viral growth for the nervous system, cell-based nanoformulations were developed with the focus on improving drug pharmacokinetics. We reasoned that ART carriage could be facilitated within blood-borne macrophages traveling across the blood-brain barrier. To test this idea, an HIV-1 encephalitis (HIVE) rodent model was used where HIV-1-infected human monocyte-derived macrophages were stereotactically injected into the subcortex of severe combined immunodeficient mice. ART was prepared using indinavir (IDV) nanoparticles (NP, nanoART) loaded into murine bone marrow macrophages (BMM, IDV-NP-BMM) after ex vivo cultivation. IDV-NP-BMM was administered i.v. to mice resulting in continuous IDV release for 14 days. Rhodamine-labeled IDV-NP was readily observed in areas of HIVE and specifically in brain subregions with active astrogliosis, microgliosis, and neuronal loss. IDV-NP-BMM treatment led to robust IDV levels and reduced HIV-1 replication in HIVE brain regions. We conclude that nanoART targeting to diseased brain through macrophage carriage is possible and can be considered in developmental therapeutics for HIV-associated neurological disease.

AB - Antiretroviral therapy (ART) shows variable blood-brain barrier penetration. This may affect the development of neurological complications of HIV infection. In attempts to attenuate viral growth for the nervous system, cell-based nanoformulations were developed with the focus on improving drug pharmacokinetics. We reasoned that ART carriage could be facilitated within blood-borne macrophages traveling across the blood-brain barrier. To test this idea, an HIV-1 encephalitis (HIVE) rodent model was used where HIV-1-infected human monocyte-derived macrophages were stereotactically injected into the subcortex of severe combined immunodeficient mice. ART was prepared using indinavir (IDV) nanoparticles (NP, nanoART) loaded into murine bone marrow macrophages (BMM, IDV-NP-BMM) after ex vivo cultivation. IDV-NP-BMM was administered i.v. to mice resulting in continuous IDV release for 14 days. Rhodamine-labeled IDV-NP was readily observed in areas of HIVE and specifically in brain subregions with active astrogliosis, microgliosis, and neuronal loss. IDV-NP-BMM treatment led to robust IDV levels and reduced HIV-1 replication in HIVE brain regions. We conclude that nanoART targeting to diseased brain through macrophage carriage is possible and can be considered in developmental therapeutics for HIV-associated neurological disease.

UR - http://www.scopus.com/inward/record.url?scp=68949102075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949102075&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0900274

DO - 10.4049/jimmunol.0900274

M3 - Article

VL - 183

SP - 661

EP - 669

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -